Monitoring immune response after CAR-T cell therapy
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at blood samples from people with B-cell lymphoma or multiple myeloma who are getting CAR-T cell therapy. The goal is to find signs in the blood that might predict how well the treatment works, which could help improve care for future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have B-cell lymphoma or multiple myeloma that has come back or not gotten better with treatment.
- Your doctor has recommended CAR-T cell therapy that targets CD19 or BCMA.
- You are willing to give blood samples for this study.
- You are not pregnant or breastfeeding.
- You do not have lymphoma in the brain or the eye.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how your immune system responds after you receive CAR-T cell therapy for multiple myeloma. The goal is to learn more about the treatment's effects and how well it works.
This study looks at how CAR-T therapy affects blood cell counts (cytopenia) in people with multiple myeloma or certain lymphomas/leukemias. You will provide biological samples to help researchers understand these effects.
This study follows patients with relapsed or hard-to-treat B-cell lymphoma who are receiving CD19-directed CAR T cell therapy. Researchers collect blood and tissue samples to better understand each patient's unique risk profile, aiming to improve how the treatment is monitored and managed.
This study looks at how your immune system responds to CAR-T cell therapy, a treatment that uses your own immune cells to fight certain cancers. By participating, you help researchers learn more about how this therapy affects the body, which could improve care for future patients.
This study looks at how well vaccines work in people with multiple myeloma or certain lymphomas after they receive CAR-T cell therapy. It aims to help doctors understand the best way to revaccinate patients to protect against preventable diseases.
This Phase 1/2 study tests C-CAR088, a lab-made immune therapy, in people with multiple myeloma that has come back or did not respond. It is for patients who have already had several standard treatments and whose disease is still measurable.
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.